SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Merz: 80% of Syrians in Germany should return in three years - 2Four new luxury hotel openings in Italy you need to know about
- 3FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- 4Investigating the Advantages of a Bank account: A Complete Aide
- 5EU waters down plans to end new petrol and diesel car sales by 2035
- Clocks to go forward one hour in Europe as summer time starts
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- People with depression can treat themselves at home with new device
- Jennifer Lawrence and Josh Hutcherson to reprise their roles for new 'Hunger Games' movie 'Sunrise on the Reaping'
- The cheap health insurance promoted by Trump officials has this catch
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- The most effective method to Pick the Best Material Organization: Insider Tips
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- New studies of old dogs help scientists understand where they came from
